Roche Says Phase III CELESTIMO Study Meets Primary Endpoint With Clinically Meaningful Reduction In Disease Progression Risk For Follicular Lymphoma Patients
Phase III CELESTIMO study met its primary endpoint at the interim analysis demonstrating a statistically significant and clinically meaningful reduction in the risk of disease progression in people with follicular
Roche's new medicine for a type of cancer passed an important test. Patients taking it got sick less often, which shows the drug is working as hoped.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.